Platelet membrane biomimetic nanoparticle-based targeted delivery system of simvastatin for the treatment of ischemic stroke

Blood-brain barrier (BBB) disruption and excessive neuroinflammation are pivotal drivers of cerebral ischemia-reperfusion injury. Although simvastatin (SV) possesses potent pleiotropic effects in promoting BBB repair and attenuating inflammation, its clinical translation for ischemic stroke is severely hampered by poor BBB penetration, low lesion accumulation, and the need for high systemic doses that increase the risk of off-target toxicity (e.g., myopathy). To address these barriers, herein, we developed a platelet membrane-biomimetic nanoparticle system (pmPLGA@SV) designed to leverage the innate affinity of platelets for injured vasculature for lesion-targeted SV delivery at a lower effective dose. Physicochemical characterization confirmed the successful cloaking of platelet membranes onto SV-loaded PLGA cores. In vitro, pmPLGA@SV demonstrated superior therapeutic versatility: it effectively scavenged reactive oxygen species in oxygen glucose deprivation/reoxygenation-treated PC12 cells and orchestrated microglial repolarization from a pro-inflammatory M1 phenotype toward an anti-inflammatory M2 state in BV2 cells, significantly modulating the secretion of IL-1β and IL-10. In vivo, pmPLGA@SV treatment dramatically reduced the cerebral infarct volume, exhibiting significant superiority over free SV. Furthermore, longitudinal behavioral assessments over 21 days demonstrated that pmPLGA@SV markedly accelerated motor and sensory-motor functional recovery, accompanied by consistent body weight regain and improved neurological scores. Mechanistically, pmPLGA@SV facilitates a synergistic therapeutic approach by mitigating neuronal oxidative stress and remodeling the inflammatory microenvironment. This study demonstrates that pmPLGA@SV serves as a robust biomimetic platform for the integrated treatment of neurovascular unit damage, offering a promising strategy for long-term neuroprotection and functional rehabilitation following ischemic stroke.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-07-23
DOI
https://doi.org/10.1371/journal.pone.0354184
Primary Topic
Neuroinflammation and Neurodegeneration Mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Platelet membrane biomimetic nanoparticle-based targeted delivery system of simvastatin for the treatment of ischemic stroke

R. Li, Lu Lin, Yu Liang, Meiting Gong et al.
PLoS ONE
Neuroinflammation and Neurodegeneration Mechanisms
article

Platelet membrane biomimetic nanoparticle-based targeted delivery system of simvastatin for the treatment of ischemic stroke

R. Li, Lu Lin, Yu Liang, Meiting Gong, Daming Sui, Qin Li
article en

Abstract

Blood-brain barrier (BBB) disruption and excessive neuroinflammation are pivotal drivers of cerebral ischemia-reperfusion injury. Although simvastatin (SV) possesses potent pleiotropic effects in promoting BBB repair and attenuating inflammation, its clinical translation for ischemic stroke is severely hampered by poor BBB penetration, low lesion accumulation, and the need for high systemic doses that increase the risk of off-target toxicity (e.g., myopathy). To address these barriers, herein, we developed a platelet membrane-biomimetic nanoparticle system (pmPLGA@SV) designed to leverage the innate affinity of platelets for injured vasculature for lesion-targeted SV delivery at a lower effective dose. Physicochemical characterization confirmed the successful cloaking of platelet membranes onto SV-loaded PLGA cores. In vitro, pmPLGA@SV demonstrated superior therapeutic versatility: it effectively scavenged reactive oxygen species in oxygen glucose deprivation/reoxygenation-treated PC12 cells and orchestrated microglial repolarization from a pro-inflammatory M1 phenotype toward an anti-inflammatory M2 state in BV2 cells, significantly modulating the secretion of IL-1β and IL-10. In vivo, pmPLGA@SV treatment dramatically reduced the cerebral infarct volume, exhibiting significant superiority over free SV. Furthermore, longitudinal behavioral assessments over 21 days demonstrated that pmPLGA@SV markedly accelerated motor and sensory-motor functional recovery, accompanied by consistent body weight regain and improved neurological scores. Mechanistically, pmPLGA@SV facilitates a synergistic therapeutic approach by mitigating neuronal oxidative stress and remodeling the inflammatory microenvironment. This study demonstrates that pmPLGA@SV serves as a robust biomimetic platform for the integrated treatment of neurovascular unit damage, offering a promising strategy for long-term neuroprotection and functional rehabilitation following ischemic stroke.

PLoS ONEVol. 21(7)
Third People's Hospital of Chengdu (CN), Chengdu Military General Hospital (CN), Chengdu Second People's Hospital (CN), Southwest Jiaotong University (CN)
Southwest Jiaotong University
Good health and well-being
Openalex Percentile: Top 11%
Neuroinflammation and Neurodegeneration Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.